Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
Silicon-based RNA delivery platform for rare disease therapeutics
SiSaf is a biopharmaceutical company developing RNA therapeutics using its proprietary platform, which combines bioabsorbable silicon with organic lipid materials to improve the stability, safety, and transfection efficiency of nucleic acid payloads. The platform addresses known limitations of conventional lipid…
Tau-targeting therapeutics and diagnostics for neurodegenerative disease
TauRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments and diagnostics for Alzheimer's disease and related neurodegenerative disorders. Its pipeline centres on tau aggregation inhibitors, which target the pathological accumulation of tau protein implicated in dementia. The company's…
European commercialisation partner for specialty and rare disease medicines
Abacus Medicine Pharmaceuticals is a commercial-stage pharmaceutical company that partners with pharmaceutical and biotechnology developers to launch and commercialise specialty medicines across Europe. It can act as a regional affiliate in selected markets or manage wider European rollouts, covering regulatory,…
Stabilised siRNA therapeutics platform targeting cardiovascular gene silencing
Argonaute RNA is a biopharmaceutical company developing small interfering RNA therapeutics for cardiovascular disease. Its siRNA platform uses proprietary chemical stabilisation to enable safe, targeted and temporary gene silencing in specific tissue cells, overcoming delivery and safety barriers that have constrained…
Sterile injectable manufacturing and fill-finish services
Wockhardt UK is the pharmaceutical manufacturing arm of an international pharmaceutical group headquartered in India. Its UK site manufactures small-volume injectable medicines in vials, ampoules and cartridges, with in-house packing, inspection and quality release. The facility supplies finished products and contract…
Implantable localised chemotherapy delivery for hard-to-treat solid tumours
CRISM Therapeutics is a clinical-stage drug delivery company developing an implantable biodegradable technology that delivers chemotherapy directly into tumours or surgical margins, reducing the systemic side effects of conventional treatment. Developed with the University of Birmingham, the company's lead programme…
Clinical-stage medicines for alcohol use disorder and PTSD
Solvonis Therapeutics is a clinical-stage biopharmaceutical company developing treatments for addiction and mental health disorders. Its lead programme is in Phase III for severe alcohol use disorder, with additional programmes addressing moderate to severe alcohol use disorder, post-traumatic stress disorder and…
Proprietary formulation platform enhancing diabetes and cardiometabolic therapies
Arecor Therapeutics is a biopharmaceutical company developing enhanced formulations of existing therapeutic products for diabetes and cardiometabolic diseases. Its proprietary formulation technology improves stability, concentration and delivery profiles for biologics and peptides, supporting both in-house programmes…
Biparatopic PD-1/VEGFR2 antibody for solid tumour oncology
Ottimo Pharma is a clinical-stage biotechnology company developing biparatopic antibody therapeutics for solid tumour cancers. Its lead programme, Jankistomig, is a first-in-class single-agent IgG antibody that simultaneously targets PD-1 for immune checkpoint inhibition and VEGFR2 to suppress tumour angiogenesis. The…
Epigenetic reprogramming and senolytic therapeutics for cancer and ageing
199 Biotechnologies is a preclinical-stage biotechnology company developing epigenetic reprogramming and senolytic therapies targeting cancer and age-related disease. Its lead programme applies partial cellular reprogramming to modify the behaviour of glioblastoma cells, reducing malignancy and reactivating natural…
Personalised T cell therapy platform for solid tumour treatment
Swarm Oncology is a pre-clinical biotechnology company developing personalised T cell therapies for advanced solid cancers. Its platform combines in vivo immune priming with proprietary ex vivo cell processing to generate large numbers of potent, non-exhausted T cells with tumour-homing phenotypes, addressing a key…
Preclinical orexin-1 addiction therapies and CNS drug discovery
TheraCryf is an AIM-listed biotechnology company developing small-molecule therapies for addiction and other neuropsychiatric conditions. Its lead orexin-1 receptor antagonist programme is completing preclinical toxicology and regulatory preparations for a first-in-human Phase 1 trial in Australia. An Australian CRO…
Specialty pharma delivering niche medicines and novel drug delivery technology
Therakind is a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient populations, including children and the elderly. The company has obtained regulatory approvals for three products across the FDA, EMA and MHRA, and has developed a proprietary intranasal dry powder…
Preclinical vaccines targeting antimicrobial-resistant bacterial infections
VacTimmune is a biotechnology company developing preventative vaccines against bacterial pathogens associated with antimicrobial resistance. Its preclinical pipeline includes candidates targeting Pseudomonas aeruginosa, Klebsiella pneumoniae and other clinically important bacteria, with an emphasis on infections…
Preclinical cardioprotective proteins for heart attack treatment
Forcefield Therapeutics is a preclinical biotechnology company developing cardioprotective protein therapies for acute myocardial infarction. Its programme uses naturally occurring proteins identified through the FunSel discovery platform to protect cardiomyocytes after a heart attack, reduce tissue damage and…
Academic drug discovery accelerator developing small molecule therapeutics
Slingshot Therapeutics is a drug discovery accelerator that identifies early-stage scientific programmes from academic institutions and advances them towards clinical development. The company provides centralised expertise, operational infrastructure, and funding to progress small molecule candidates through…
Light-activated small molecule therapies for oral cancer and wound care
LightOx is a biotechnology company developing light-activated small molecule therapeutics for cancer and infection. Its lead candidate LXD191 is a topically applied photosensitising compound targeting early-stage oral cancer and pre-cancerous lesions, activated by a specific wavelength of light to generate reactive…
Cannabinoid medicines, neuroscience and oncology drug development
Jazz Pharmaceuticals is a global biopharmaceutical company focused on medicines for neuroscience and oncology. Its UK operations, centred at Kent Science Park in Sittingbourne, form the heart of its global cannabinoid manufacturing and research activities, inherited through its 2021 acquisition of GW Pharmaceuticals…
TCR therapeutic discovery platform targeting solid tumours
T-Cypher Bio is a pre-clinical biotechnology company developing T-cell receptor therapeutics using its proprietary platform, which integrates immunopeptidomics, bead-display microfluidics, and immune synapse mapping to identify novel intracellular targets and potent TCRs directly from patient tissue. The approach…
Pharmaceutical company in cardiometabolic, oncology, and immunology
Eli Lilly and Company is a multinational pharmaceutical company with UK operations headquartered in Basingstoke and an R&D site in Bracknell. Founded in 1876, Lilly's UK affiliate has operated since 1934 and employs approximately 700 people across regulatory, medical affairs, and research functions. The company…